F-star gets A star treatment with $1.4B Janssen pact

 

To view this email as a web page, click here

Today's Rundown

Featured Story

Amid Amgen's similar struggles, AstraZeneca slams the brakes on MCL-1 blood cancer drug

AstraZeneca has paused an active phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing the need to suss out a potential safety issue.

read more

Top Stories

Stealth's not so sneaky strategy to file unprepared drug application foiled by FDA

It was a bold strategy, filing a drug the FDA clearly said was not ready for prime time, but Stealth BioTherapeutics did it anyway. Today, its chickens have come home to roost.

read more

F-star shoots for the moon with massive $1.35B J&J biobucks deal for 5 bispecifics

Add Johnson & Johnson's Janssen Biotech to the list of Big Pharmas lining up at the doors of 2011 Fierce 15 winner F-star Therapeutics. The $17.5 million upfront, $1.35 billion biobucks pact grants Janssen an exclusive license to up to five novel bispecific antibodies.

read more

Sponsored: Considerations for Laboratory-Related Operational and Patient Burden in Decentralized Clinical Trials. Clinical Lab Testing in Your Home: Fact or Fiction?

Clinical lab testing at home - fact or fiction? Many operational and patient-related considerations must be taken when using a decentralized approach to specimen collection at or near the trial participant's home.

read more

Galera shares slide nearly 70% as radiotherapy complication drug flunks out of phase 3

Galera Therapeutics’ drug for a radiotherapy complication failed to reduce incidences of the debilitating condition called severe oral mucositis during a phase 3 trial.

read more

Receptos founder returns with ShouTi and $100M for oral drugs to treat chronic diseases

ShouTi raised $100 million in series B funds to bankroll clinical trials of its oral, small-molecule treatments in chronic diseases spanning cardiovascular, metabolic and pulmonary conditions. The San Francisco and Shanghai biotech has raised $158 million since its 2019 inception.

read more

Chase, after selling last biotech to Allergan, gets cash to start pivotal trials in depression, Parkinson's 

Chase Therapeutics is heading into pivotal trials. Armed with $20 million, the biotech plans to start phase 3 clinical trials of candidates based on an old Boehringer Ingelheim drug in major depressive disorder (MDD) and Parkinson’s disease.

read more

Takeda crashes out of Wave discovery pact at cost of $23M

Takeda’s interest in Wave Life Sciences’ discovery programs has ebbed, leading it to exit that part of its alliance with the biotech while keeping the option to license a trio of more advanced programs.

read more

Injured tumor cells activate immuno-oncology drugs to combat breast cancer and melanoma in mice

Scientists at the MIT Center for Precision Cancer Medicine developed a method for removing tumor cells, treating them with chemotherapy and then combining them with checkpoint-inhibiting drugs to stimulate an immune attack against cancer. In mouse models of melanoma and breast cancer, the technique eliminated 40% of tumors, they reported.

read more

Intrivo launches at-home COVID test that returns results in 10 minutes via AI-powered app

There’s an app for just about everything these days—including, now, to generate the results of an at-home COVID-19 test.

read more

Security flaws in health apps, APIs potentially put millions of patient records at risk, report finds

Even when electronic health record systems are secure, the apps and aggregators using them may not be. In a new report, "recovering hacker" Alissa Knight tested the vulnerability of three interfaces linking EHR servers to third-party aggregators—and gained access to 4 million records with a single login.

read more

Failed cancer immunotherapies cost Medicare hundreds of millions. How should FDA revamp accelerated approvals?

A recent FDA review of past conditional go-aheads for cancer immunotherapies has led to several withdrawals. Health policy and economics researchers see the campaign as another opportunity to push for a revamp of the agency’s accelerated approval pathway.

read more

 

Resources

Whitepaper: Enhance the cost-effectiveness of your cGMP chemical supply chain

Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific

Research: eTMF Implementation Quick Guide

Check out the eTMF Implementation Quick Guide to see a checklist TMF experts developed to help you reduce risks, maintain compliance, and establish effective processes in your eTMF.

Whitepaper: Modernizing Key Clinical Trial Processes with Artificial Intelligence

This whitepaper addresses where AI can make the biggest impact in clinical trials.

Free Infographic: Identifying Opportunities for Biotech Scale-Up

Looking to accelerate your biotech company, but not sure where to start?

Paid Marketplace: Online Graduate Programs Designed for Your Career

Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Whitepaper: Transform LIMS Data into Action-Ready Insights with Advanced Analytics

Shift from data collection to data science. Add advanced analytics to your lab informatics platform to yield valuable, action-ready insights from LIMS and other data.

Whitepaper: Clinical trial simulation: Advanced modeling techniques enable data-driven supply chain planning

Integrate supply chain simulation into your early clinical trial planning to minimize risk in an uncertain supply chain environment, improve supply chain outcomes, and help streamline time-to-market for innovative therapies.

Whitepaper: Big Challenges for Small Sponsors: Competition in Oncology Research

Every biopharma sponsor faces the challenge of initiating, running and closing trials on time, but oncology studies pose several unique hurdles.

eBook: Get solutions to market faster

Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization.

Events